203 related articles for article (PubMed ID: 27197306)
21. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
22. Secreted Heat Shock Protein 90α Attenuated the Effect of Anticancer Drugs in Small-Cell Lung Cancer Cells Through AKT/GSK3β/β-Catenin Signaling.
Du Y; Wu J; Luo L
Cancer Control; 2018; 25(1):1073274818804489. PubMed ID: 30282477
[TBL] [Abstract][Full Text] [Related]
23. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
Kim EY; Jung JY; Kim A; Chang YS; Kim SK
Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
[TBL] [Abstract][Full Text] [Related]
24. The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.
Bieghs L; Lub S; Fostier K; Maes K; Van Valckenborgh E; Menu E; Johnsen HE; Overgaard MT; Larsson O; Axelson M; Nyegaard M; Schots R; Jernberg-Wiklund H; Vanderkerken K; De Bruyne E
Oncotarget; 2014 Nov; 5(22):11193-208. PubMed ID: 25008202
[TBL] [Abstract][Full Text] [Related]
25. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
26. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
27. Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung.
Wang WZ; Shilo K; Amann JM; Shulman A; Hojjat-Farsangi M; Mellstedt H; Schultz J; Croce CM; Carbone DP
Cell Death Dis; 2021 Jun; 12(6):577. PubMed ID: 34088900
[TBL] [Abstract][Full Text] [Related]
28. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
[TBL] [Abstract][Full Text] [Related]
29. Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.
Sakakibara-Konishi J; Ikezawa Y; Oizumi S; Kikuchi J; Kikuchi E; Mizugaki H; Kinoshita I; Dosaka-Akita H; Nishimura M
Int J Clin Oncol; 2017 Apr; 22(2):257-268. PubMed ID: 27816990
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
[TBL] [Abstract][Full Text] [Related]
31. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
He L; Torres-Lockhart K; Forster N; Ramakrishnan S; Greninger P; Garnett MJ; McDermott U; Rothenberg SM; Benes CH; Ellisen LW
Cancer Discov; 2013 Mar; 3(3):324-37. PubMed ID: 23274910
[TBL] [Abstract][Full Text] [Related]
32. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
[TBL] [Abstract][Full Text] [Related]
33. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
[TBL] [Abstract][Full Text] [Related]
34. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.
Ruvolo PP; Ruvolo VR; Benton CB; AlRawi A; Burks JK; Schober W; Rolke J; Tidmarsh G; Hail N; Davis RE; Andreeff M
Biochim Biophys Acta; 2016 Apr; 1863(4):562-71. PubMed ID: 26704388
[TBL] [Abstract][Full Text] [Related]
35. Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis.
Zhang E; Yin S; Lu X; Ye L; Fan L; Hu H
Nutrients; 2018 Mar; 10(3):. PubMed ID: 29543705
[TBL] [Abstract][Full Text] [Related]
36. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF
J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
[TBL] [Abstract][Full Text] [Related]
37. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
Hauck P; Chao BH; Litz J; Krystal GW
Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
[TBL] [Abstract][Full Text] [Related]
38. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer.
Nakajima W; Hicks MA; Tanaka N; Krystal GW; Harada H
Cell Death Dis; 2014 Feb; 5(2):e1052. PubMed ID: 24525728
[TBL] [Abstract][Full Text] [Related]
39. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
40. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Fan W; Tang Z; Yin L; Morrison B; Hafez-Khayyata S; Fu P; Huang H; Bagai R; Jiang S; Kresak A; Howell S; Vasanji A; Flask CA; Halmos B; Koon H; Ma PC
Cancer Res; 2011 Jul; 71(13):4494-505. PubMed ID: 21555370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]